A growing body of evidence indicates a role for D 3 receptors in L-DOPA-induced dyskinesias. This involvement could be amenable to non-invasive in vivo analysis using functional neuroimaging. With this goal, we examined the hemodynamic response to the dopamine D 3 -preferring agonist 7-hydroxy-N,N-di-n-propyl-2 aminotetralin (7-OHDPAT) in naïve, parkinsonian and L-DOPA-treated, dyskinetic rodents and primates using pharmacological MRI (phMRI) and relative cerebral blood volume (rCBV) mapping. Administration of 7-OHDPAT induced minor negative changes of rCBV in the basal ganglia in naïve and parkinsonian animals. Remarkably, the hemodynamic response was reversed (increased rCBV) in the striatum of parkinsonian animals rendered dyskinetic by repeated L-DOPA treatment. Such increase in rCBV is consistent with D 1 receptorlike signaling occurring in response to D 3 stimulation, demonstrates a dysregulation of dopamine receptor function in dyskinesia and provides a potentially novel means for the characterization and treatment of L-DOPA-induced dyskinesia in patients.
Long-term dopamine (DA) replacement therapy in Parkinson's disease (PD) often leads to development of abnormal motor response and dyskinesia (Olanow et al., 2004) through poorly understood mechanisms. DA modulates the basal ganglia output through opposite effects on the postsynaptic DA receptors: D 1 facilitation and D 2 -like (D 2 and D 3 ) inhibition (Beaulieu et al., 2005) . Anatomically, D 1 and D 2 -like receptors are partially segregated into the striatonigral ("direct") and striatopallidal ("indirect") projections or pathways (Gerfen et al., 1990) . However, there is evidence of substantial co-localization of functional D 1 -and D 2 -like receptors on striatal medium spiny projection neurons (Aizman et al., 2000; Pollack, 2004) implying that cross-talk may occur both at circuitry and intracellular levels. DA receptors are 7 transmembrane G-protein-coupled receptors: D 1 receptors are coupled to G αs/olf, increase cAMP levels and phosphorylation of DARPP-32 and proteins downstream (Bonci and Hopf, 2005) . D 2 are linked to Gαi, inhibit adenyl cyclases and activate G-protein-coupled inward-rectifying potassium channels (Girk) and phosphatases (Bonci and Hopf, 2005) . D 3 have no net effect on cAMP levels and may couple to both Gs and i proteins (Ilani et al., 2002) . Notably, D 1 and D 2 /D 3 agonists induce opposite hemodynamic changes in the striatum measured by functional pharmacologic (ph)MRI; D 1 agonists increase relative cerebral blood volume (rCBV) while D 2 and D 3 agonists decrease it (Chen et al., 2005; Choi et al., 2006) . Pramipexole, a D 3 -preferring agonist, has been shown to reduce cerebral blood flow in cingulate and orbitofrontal areas in monkeys in a PET study (Black et al., 2002) . These opposite effects correlate well with the D 1 -mediated facilitation and D 2 gating roles on glutamate transmission in the striatum.
While D 3 receptors are not highly expressed in the motor regions of the striatum (Murray et al., 1994; Sokoloff et al., 1990) , there is compelling evidence from postmortem studies, of L-DOPA induction of ectopic D 3 receptor expression in D 1 -expressing medium spiny neurons in the striatum of parkinsonian rats (Bordet et al., 1997; Bordet et al., 2000) and macaques (Bezard et al., 2003; Quik et al., 2000) . Furthermore, both the presence of L-DOPAinduced dyskinesias in primates (Bezard et al., 2003) and sensitization to L-DOPA in rats (Bordet et al., 1997; Bordet et al., 2000; Guillin et al., 2003) have been correlated with changes in D 3 receptor expression in postmortem analyses. In this study we examined in vivo hemodynamic changes in response to D 3 activation using ph MRI and (7-hydroxy-N,N-di-n-propyl-2 aminotetralin) 7-OHDPAT, in naïve, parkinsonian and L-DOPA-treated rats and primates. 7-OHDPAT has a 10-fold higher affinity for the D 3 (Missale et al., 1998; Sokoloff et al., 1990) compared to the D 2 receptor.
